Seizure was within 12.8% from the patients and intracranial hypertension presented in 43.6% of the patients at diagnosis. prognoses. Gene and large sample tissue microarrays showed high expression of SAMSN1 in glioma particularly in GBM. Survival analysis based on the TCGA GBM data matrix and TMA Rabbit Polyclonal to OR10C1 multi-grade glioma dataset found that SAMSN1 expression was closely related to the prognosis of GBM, either PFS or OS (P<0.05). Multivariate survival analysis with Cox proportional hazards regression models confirmed that high expression of SAMSN1 was a strong risk factor for PFS and OS of GBM patients. == Conclusion == SAMSN1 is over-expressed in glioma as compared with that found in normal brains, especially in GBM. High expression of SAMSN1 is a significant risk factor for the progression free and overall survival of GBM. == Introduction == Malignant glioma is the most common and lethal form of cancer that originates from the central nervous system. Glioblastoma multiforme (GBM) also named as grade IV astrocytoma by the World Health Organization (WHO), accounts for approximately 60 to 70% of malignant glioma and is the most biologically aggressive subtype[1]. The prognosis of GBM is rather dismal and the average survival time is only 14.6 months from initial diagnosis, even when considering the current standards of treatment, which includes surgery, followed by radiotherapy and SR9009 Temozolomide-based chemotherapy [2]. Since current treatment gained little benefit in the setting of GBM, greater attention has been paid to the expression of specific molecular markers with the goal of determining their possible prognostic and therapeutic significance. SAMSN1 (SAM domain, SH3 domain, and nuclear localization signals 1), also termed HACS1/SLY2/NASH1, is a member of a family of three adapter proteins that are highly homologous and characterized by the presence of protein-protein interaction domains. Proteins with the sterile motif (SAM) domain are able to associate with each other and can also self associate. Chimeric fusion of the SAM domain with the PDGF receptor [3], AML1 [4], c-Abl [5], and JAK2 [6] can promote the oncogenic transformation of the SAM domain. Src homology 3 (SH3) domains are known to mediate interactions of proteins in a number of signal transduction pathways. The presence of these domains in a protein is often indicative of adaptor or scaffolding functions. The SR9009 SAMSN1 gene localizes to a region on human chromosome 21 (21q11.2). The region is subject to frequent translocation events in hematopoietic malignancies. The transcript of SAMSN1 has been found in acute myeloid leukemia, lymphoma, and multiple myeloma cell-lines [7]. Evidence is lacking with regard the role that SAMSN1 plays in certain solid tumors. A recent study found that SAMSN1 was positively associated with, and has predictive value in the setting of ulcerative colitis-associated colorectal cancer [8]. Another study found that the expression of SAMSN1 was reduced in lung cancer cell-lines. However, introduction of the expression vector for this gene did not result in any significant growth inhibition [9]. In central nervous system, SAMSN1 is expressed at a low level in normal brain [10], SR9009 and the SAMSN1 protein might exert an influence on blood vessel formation during normal brain development [11]. The role of SAMSN1 in glioma remains unclear, and to the best of our knowledge, there has not been a prior report of its functional expression and prognostic value in glioma. Although there has been no previous report about the action of SAMSN1 in glioma, a former study has shown that SAMSN1 expression can be increased in B lymphocyte by IL-4 stimulation through both STAT6 and PI3k/PKC/NF-B pathways [10]. PI3K and NF-kB are important molecules participating in GBM pathogenesis. RTK/RAS/PI3K signaling pathway have been found to be one major pathway that were altered in GBM (altered in 88% human GBM)[12]. Furthermore, NF-kB is a downstream molecule of PI3K signaling, and is a major anti- apoptotic mediator that is over-expressed in glioma [13]. In the nucleus, SAMSN1 binds to Sin3-associated polypeptide 30 (SAP30) and histone deacetylase 1 (HDAC1), and forms a stable ternary complex [14]. The activity of HDAC1 was thus increased. It was reported that HDAC1 siRNA could elicit a concentration-dependent inhibition of HeLa cell proliferation [15]. In addition, HDAC1 has previously been found to be associated with many cancers, including glioma [16], gastric cancers [17], prostate cancers [18], liver cancers [19], breast cancers [20], and melanoma [21]. Thus it is reasonable to speculate that.